{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-25-016473","form_type":"8-K/A","ticker":"HROW","cik":"0001360214","company_name":"HARROW, INC.","filed_at":"2025-10-01T23:59:59+00:00","discovered_at":"2026-05-14T18:02:39.225865+00:00","generated_at":"2026-05-17T05:03:30.245408+00:00","sec_items":["1.01","9.01"],"event_type":"m_and_a","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Harrow to acquire Melt Pharmaceuticals for $0.50/share; already owns 45%","bullets":["Harrow will pay $0.50 per share of Melt Common Stock for the remaining ~55% it does not already own.","Melt is a clinical-stage company developing MELT-300 for procedural sedation in cataract surgery.","Transaction approved by special committees of both boards, each receiving fairness opinions.","Harrow and Melt entered a Milestone Payment Agreement tied to regulatory and sales milestones.","Merger Sub will merge with and into Melt; Melt will survive as wholly owned subsidiary of Harrow."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-25-016473","json":"https://secwatch.observer/filing/0001493152-25-016473.json","markdown":"https://secwatch.observer/filing/0001493152-25-016473.md","text":"https://secwatch.observer/filing/0001493152-25-016473.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225016473/0001493152-25-016473-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1360214/000149315225016473/form8-ka.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T05:03:30.245408+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}